Post-exposure prophylaxis revisited: new CDC guidelines. Centers for Disease Control and Prevention.
Flexner
C
C
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002487:Centers for Disease Control and Prevention, U.S.; D004359:Drug Therapy, Combination; D017408:Guidelines as Topic; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D017758:Infectious Disease Transmission, Patient-to-Professional; D016602:Needlestick Injuries; D016273:Occupational Exposure; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine